| __timestamp | Alnylam Pharmaceuticals, Inc. | Genmab A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 505679000 |
| Thursday, January 1, 2015 | 276495000 | 487656000 |
| Friday, January 1, 2016 | 382392000 | 660876000 |
| Sunday, January 1, 2017 | 390635000 | 874278000 |
| Monday, January 1, 2018 | 505420000 | 1431159000 |
| Tuesday, January 1, 2019 | 655114000 | 2386000000 |
| Wednesday, January 1, 2020 | 654819000 | 3137000000 |
| Friday, January 1, 2021 | 792156000 | 4181000000 |
| Saturday, January 1, 2022 | 883015000 | 5562000000 |
| Sunday, January 1, 2023 | 1004415000 | 7630000000 |
| Monday, January 1, 2024 | 1126232000 | 9748000000 |
Data in motion
In the ever-evolving world of biotechnology, research and development (R&D) are the lifeblood of innovation. Over the past decade, Alnylam Pharmaceuticals, Inc. and Genmab A/S have been at the forefront, investing heavily in R&D to drive breakthroughs in medical science. From 2014 to 2023, Alnylam's R&D expenses surged by over 400%, reflecting its commitment to pioneering RNA interference therapies. Meanwhile, Genmab's R&D spending skyrocketed by an impressive 1,400%, underscoring its focus on antibody therapeutics.
In 2023, Genmab's R&D budget was nearly 7.6 times that of Alnylam, highlighting its aggressive expansion strategy. This trend showcases the competitive landscape of biotech, where companies are racing to develop the next big treatment. As these giants continue to push the boundaries of science, their R&D investments are not just expenditures but strategic bets on the future of healthcare.
Who Prioritizes Innovation? R&D Spending Compared for Eli Lilly and Company and Alnylam Pharmaceuticals, Inc.
R&D Spending Showdown: AbbVie Inc. vs Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. vs Teva Pharmaceutical Industries Limited: Strategic Focus on R&D Spending
R&D Insights: How Alnylam Pharmaceuticals, Inc. and PTC Therapeutics, Inc. Allocate Funds
R&D Insights: How Alnylam Pharmaceuticals, Inc. and Perrigo Company plc Allocate Funds
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Veracyte, Inc.
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.
Analyzing R&D Budgets: Genmab A/S vs Incyte Corporation
Genmab A/S or Sarepta Therapeutics, Inc.: Who Invests More in Innovation?
Genmab A/S vs BioMarin Pharmaceutical Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Genmab A/S vs Apellis Pharmaceuticals, Inc.